Indefinite Delivery Contract 75D30125D20478
Award Date
7/1/25
Last Date to Order
6/30/26
Federal Agency
CDC Pittsburgh
Awardee
Dynavax Technologies Corporation
Ultimate Awardee
Not listed
NAICS Category
325412 - Pharmaceutical Preparation Manufacturing
PSC Category
6505 - Drugs And Biologicals
Federal Contract Vehicle
Pricing Type
Firm Fixed Price
Legislative Mandate
Not listed
National Interest Action
None
Award Type
Multiple
Primary Consortia Member
Not listed
Similar IDVs
This Indefinite Delivery Contract (IDC) was awarded by the Centers for Disease Control and Prevention (CDC) to Dynavax Technologies Corporation, a biopharmaceutical company focused on immune system responses. The contract, valued at $28,105,875.00, covers the provision of adult vaccines to support the CDC's national immunization programs. As a multiple-award IDC, the contract allows for the continued issuance of task orders to Dynavax over the performance period, which runs through June 30,...
Dynavax Technologies Corporation was awarded a single-award Indefinite Delivery Contract by the Centers for Disease Control and Prevention. The contract has a potential value of $27.4M to deliver adult vaccines in support of the CDC's national immunization programs. No set-asides were specified. Performance will take place through June 2021. Under this contract, Dynavax will provide a range of pharmaceutical products and services. This includes delivering adult vaccines to the CDC to support its...
The Centers for Disease Control and Prevention (CDC) has awarded an Indefinite Delivery, Indefinite Quantity (IDIQ) contract to Dynavax Technologies Corporation, valued at up to $56,203,651.08, to supply various adult vaccines over a one-year period from July 1, 2023 through June 30, 2024. The vaccines to be delivered include hepatitis A, hepatitis B, hepatitis A & B combination, pneumococcal polysaccharide, tetanus and diphtheria toxoids, herpes zoster, tetanus, reduced diphtheria toxoid...
The Centers for Disease Control and Prevention (CDC) has awarded a $56.2 million Indefinite Delivery Indefinite Quantity (IDIQ) contract to Dynavax Technologies Corporation, a biopharmaceutical company, for the purchase of 12 standard adult vaccines. This contract will support the CDC's immunization awardees, including state health departments, in their adult immunization programs authorized under Section 317(j) of the Public Health Service Act. The contract has a one-year period of...
The Centers for Disease Control and Prevention (CDC), National Center for Immunization and Respiratory Diseases (NCIRD) awarded an Indefinite Delivery Indefinite Quantity (IDIQ) contract worth up to $58,450,000 to Dynavax Technologies Corporation (Dynavax) for the purchase of various adult vaccines. The contract has a period of performance from July 1, 2024 to June 30, 2025 and is not set-aside. The required vaccine types include Hepatitis A, Hepatitis B, Hepatitis A&B combination, Herpes...
This federal Indefinite Delivery Contract (IDC) was awarded by the Centers for Disease Control and Prevention (CDC) to Glaxosmithkline, LLC, a foreign-owned, for-profit pharmaceutical company, for the procurement of adult vaccines. The IDC has a total ceiling value of $105,362,800 and a period of performance through June 30, 2026. The contract is a multiple award vehicle that does not have any set-aside designations. It supports critical national immunization efforts by allowing the CDC and...
The indefinite delivery contract (IDC) 75D30120D08572 was awarded by the Centers for Disease Control and Prevention (CDC) to Glaxosmithkline, LLC for the provision of vaccines for adults. The $131,225,875 multiple award contract has a period of performance through June 30, 2021. Glaxosmithkline, a pharmaceutical company, will supply a range of vaccines and antiviral medications to support disease prevention efforts, immunization programs, and healthcare services for various U.S. government...
This indefinite delivery contract (IDC) was awarded by the Centers for Disease Control and Prevention (CDC) to Glaxosmithkline, LLC to procure a variety of adult vaccines over a 1-year period from July 1, 2021 to June 30, 2022. The $156,027,900 multiple award IDC contains no set-aside designation and requires delivery within 15 business days of order placement to destinations across the United States to support state health departments and immunization programs. The original solicitation...
This Indefinite Delivery Contract (IDC) was awarded by the Centers for Disease Control and Prevention (CDC), a civilian agency, to Glaxosmithkline Holdings (Americas) Inc. as the prime contractor. The contract has a ceiling value of $261,469,025.27 and a period of performance ending on June 30, 2011. The purpose of this IDC is to provide adult vaccines, as part of the CDC's Adult Vaccine Contract 2010 - 2011 program. The contract was not set aside for any specific business category. It was...
This indefinite delivery contract (IDC) was awarded by the Centers for Disease Control and Prevention (CDC) to Seqirus USA Inc., a global biotechnology company specializing in influenza vaccine development, manufacturing, and delivery. The $253,319,000 multiple-award IDC has a period of performance from December 31, 2024 to February 28, 2026 and is intended to provide adult flu vaccines to support the CDC's annual immunization programs. Seqirus, through its Seqirus USA, Inc. division, is a...